Quantcast

Latest Postherpetic neuralgia Stories

2011-09-07 12:15:48

A Cochrane Review of data relating to about 45,000 patients involved in approximately 350 individual studies has provided an evaluation of the effect you can expect to get if you take commonly used painkillers at specific doses. The review also identifies pain killers for which there is only poor or no reliable evidence. This review will help doctors and patients to make evidence informed decisions of which pain killers to use, and is published in the latest edition of The Cochrane Library....

2011-08-12 07:00:00

SAN MATEO, Calif., Aug. 12, 2011 /PRNewswire/ -- NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, is scheduled to present at the 2011 Wedbush Life Sciences: Management Access Conference to be held August 16-17, 2011, at Le Parker Meridien in New York, NY. Mr. Ghiglieri will also be...

2011-08-09 07:00:00

SAN MATEO, Calif., Aug. 9, 2011 /PRNewswire/ -- Recent Highlights: Completed equity and debt financing totaling $40 million Qutenza® (capsaicin) 8% patch launch in U.S. building momentum in large U.S. institutions; 432 institutions purchased as of 2Q11, up 34% from 1Q11 Sales of Qutenza to end user customers increased 23% over 1Q11 2Q11 revenue totaled $2.5 million including $0.5 million U.S. Qutenza product revenue EU launch by Astellas advancing, with Qutenza...

2011-08-08 15:06:00

SAN MATEO, Calif., Aug. 8, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, today announced that it has entered into a $20 million loan agreement with Hercules Technology Growth Capital, Inc. (Nasdaq: HTGC). The loan agreement includes both a $5 million accounts receivable line of credit and a $15 million term loan. Proceeds are expected to be used to further support commercialization activities for...

2011-08-02 08:00:00

SAN MATEO, Calif., Aug. 2, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Tuesday, August 9, 2011 at 8:30 a.m. EDT (5:30 a.m. PDT) to report results for its second quarter ended June 30, 2011 and to provide an update on the U.S. commercial launch of Qutenza® (capsaicin) 8% patch for the management of neuropathic pain...

2011-06-16 07:00:00

SAN MATEO, Calif., June 16, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN). NGX-1998 is being developed to provide safety, efficacy and tolerability that is at least comparable to...

2011-06-08 21:41:55

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack. The findings, which support a long-held view on how MS may develop, are published in The Journal of Infectious Diseases and now available online (http://jid.oxfordjournals.org/content/early/2011/06/07/infdis.jir239.abstract). MS is an autoimmune disease that affects the brain and spinal cord, leading to inflammation...

2011-05-05 06:30:00

SAN MATEO, Calif., May 5, 2011 /PRNewswire/ -- NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 10th Annual JMP Securities Research Conference, to be held May 9-11, 2011, in San Francisco, CA. Event: 10th Annual JMP Securities Research Conference Date: Monday, May 9, 2011 Time:...

2011-05-02 05:00:00

VANCOUVER, British Columbia, May 2, 2011 /PRNewswire/ -- Xenon Pharmaceuticals Inc. (Xenon) announced today that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with Post Herpetic Neuralgia (PHN). Xenon is developing XEN402 as a topical treatment for a variety of painful disorders including PHN, as it specifically targets sodium channels such as Nav1.7. Sodium channels are highly expressed in sensory nerve endings and can be...


Latest Postherpetic neuralgia Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »
Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related